Nontuberculous mycobacterial pulmonary disease and the potential role of SPR720

References

• Falkinham JO. 3rd. Environmental sources of nontuberculous mycobacteria. Clin Chest Med. 2015 Mar;36(1):35–41. doi: 10.1016/j.ccm.2014.10.003
   PubMed Web of Science ®Google Scholar
• LPSN. Genus Mycobacterium Sudbury, Massachusetts2023. [cited 2023 Jun 6]. Available from: https://lpsn.dsmz.de/genus/mycobacterium
   Google Scholar
• Prevots DR, Marras TK. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. Clin Chest Med. 2015 Mar;36(1):13–34. doi: 10.1016/j.ccm.2014.10.002
   PubMed Web of Science ®Google Scholar
• Hoefsloot W, van Ingen J, Andrejak C, et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J. 2013 Dec;42(6):1604–1613. doi: 10.1183/09031936.00149212
   PubMed Web of Science ®Google Scholar
• Zweijpfenning SMH, Ingen JV, Hoefsloot W. Geographic distribution of nontuberculous mycobacteria isolated from clinical specimens: a systematic review. Semin Respir Crit Care Med. 2018 Jun;39(3):336–342. doi: 10.1055/s-0038-1660864
   PubMed Web of Science ®Google Scholar
• Dahl VN, Molhave M, Floe A, et al. Global trends of pulmonary infections with nontuberculous mycobacteria: a systematic review. Int J Infect Dis. 2022 Dec;125:120–131. doi: 10.1016/j.ijid.2022.10.013
   PubMed Web of Science ®Google Scholar
• Marras TK, Campitelli MA, Kwong JC, et al. Risk of nontuberculous mycobacterial pulmonary disease with obstructive lung disease. Eur Respir J. 2016 Sep;48(3):928–931. doi: 10.1183/13993003.00033-2016
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Marras TK, Adjemian J, et al. Incidence and prevalence of nontuberculous mycobacterial lung disease in a large U.S managed care Health plan, 2008-2015. Ann Am Thorac Soc. 2020 Feb;17(2):178–185. doi: 10.1513/AnnalsATS.201804-236OC
   PubMed Web of Science ®Google Scholar
• Wang PH, Pan SW, Wang SM, et al. The impact of nontuberculous mycobacteria species on mortality in patients with nontuberculous mycobacterial lung disease. Front Microbiol. 2022;13:909274. doi: 10.3389/fmicb.2022.909274
   PubMed Web of Science ®Google Scholar
• Huang HL, Cheng MH, Lu PL, et al. Epidemiology and predictors of NTM pulmonary infection in Taiwan - a retrospective, five-year multicenter study. Sci Rep. 2017 Nov 24;7(1):16300. doi: 10.1038/s41598-017-16559-z
   PubMedGoogle Scholar
• Zhu YN, Xie JQ, He XW, et al. Prevalence and clinical characteristics of nontuberculous mycobacteria in patients with Bronchiectasis: a systematic review and meta-analysis. Respiration. 2021;100(12):1218–1229. doi: 10.1159/000518328
   PubMed Web of Science ®Google Scholar
• Chu H, Zhao L, Xiao H, et al. Prevalence of nontuberculous mycobacteria in patients with bronchiectasis: a meta-analysis. Arch Med Sci. 2014 Aug 29;10(4):661–668. doi: 10.5114/aoms.2014.44857
   PubMed Web of Science ®Google Scholar
• Zhou Y, Mu W, Zhang J, et al. Global prevalence of non-tuberculous mycobacteria in adults with non-cystic fibrosis bronchiectasis 2006-2021: a systematic review and meta-analysis. BMJ Open. 2022 Aug 1;12(8):e055672. doi: 10.1136/bmjopen-2021-055672
   PubMed Web of Science ®Google Scholar
• Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007 Feb 15;175(4):367–416. doi: 10.1164/rccm.200604-571ST
   PubMed Web of Science ®Google Scholar
• Chan ED, Iseman MD. Underlying host risk factors for nontuberculous mycobacterial lung disease. Semin Respir Crit Care Med. 2013 Feb;34(1):110–123. doi: 10.1055/s-0033-1333573
   PubMed Web of Science ®Google Scholar
• Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Clin Infect Dis. 2020 Aug 14;71(4):905–913. doi: 10.1093/cid/ciaa1125
   PubMed Web of Science ®Google Scholar
• Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J. 2020 Jul;56(1):2000535. doi:10.1183/13993003.00535-2020
   PubMed Web of Science ®Google Scholar
• Im Y, Hwang NY, Kim K, et al. Impact of time between diagnosis and treatment for nontuberculous mycobacterial pulmonary disease on culture conversion and all-cause mortality. Chest. 2022 May;161(5):1192–1200. doi: 10.1016/j.chest.2021.10.048
   PubMed Web of Science ®Google Scholar
• Diel R, Nienhaus A, Ringshausen FC, et al. Microbiologic outcome of interventions against Mycobacterium avium complex pulmonary disease: a systematic review. Chest. 2018 Apr;153(4):888–921. doi: 10.1016/j.chest.2018.01.024
   PubMed Web of Science ®Google Scholar
• Jarand J, Davis JP, Cowie RL, et al. Long-term follow-up of Mycobacterium avium complex lung disease in patients treated with regimens including clofazimine and/or rifampin. Chest. 2016 May;149(5):1285–1293. doi: 10.1378/chest.15-0543
   PubMed Web of Science ®Google Scholar
• Wallace RJ Jr., Brown-Elliott BA, McNulty S, et al. Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease. Chest. 2014 Aug;146(2):276–282. doi: 10.1378/chest.13-2538
   PubMed Web of Science ®Google Scholar
• Boyle DP, Zembower TR, Qi C. Relapse versus reinfection of Mycobacterium avium complex pulmonary disease. Patient characteristics and Macrolide susceptibility. Ann Am Thorac Soc. 2016 Nov;13(11):1956–1961. doi: 10.1513/AnnalsATS.201605-344BC
   PubMed Web of Science ®Google Scholar
• Koh WJ, Moon SM, Kim SY, et al. Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype. Eur Respir J. 2017 Sep;50(3):1602503. doi: 10.1183/13993003.02503-2016
   PubMed Web of Science ®Google Scholar
• Ku JH, Henkle E, Aksamit TR, et al. Treatment of nontuberculous mycobacterial (NTM) pulmonary infection in the US bronchiectasis and NTM registry: treatment patterns, adverse events, and adherence to American thoracic society/infectious disease society of America treatment guidelines. Clin Infect Dis. 2023 Jan 13;76(2):338–341. doi: 10.1093/cid/ciac788
   PubMed Web of Science ®Google Scholar
• Morimoto K, Namkoong H, Hasegawa N, et al. Macrolide-resistant Mycobacterium avium complex lung disease: analysis of 102 consecutive cases. Ann Am Thorac Soc. 2016 Nov;13(11):1904–1911. doi: 10.1513/AnnalsATS.201604-246OC
   PubMed Web of Science ®Google Scholar
• Kwak N, Park J, Kim E, et al. Treatment outcomes of Mycobacterium avium complex lung disease: a systematic review and meta-analysis. Clin Infect Dis. 2017 Oct 1;65(7):1077–1084. doi: 10.1093/cid/cix517
   PubMed Web of Science ®Google Scholar
• Kwon YS, Kwon BS, Kim OH, et al. Treatment outcomes after discontinuation of ethambutol due to adverse events in Mycobacterium avium complex lung disease. J Korean Med Sci. 2020 Mar 9;35(9):e59. doi: 10.3346/jkms.2020.35.e59
   PubMed Web of Science ®Google Scholar
• Balavoine C, Blanc F-X, Lanotte P, et al. Adverse events during treatment of nontuberculous mycobacterial lung disease: do they really matter? Eur Respir J. 2018;52(suppl 62):PA2664. doi: 10.1183/13993003.congress-2018.PA2664
   Google Scholar
• Kim DH, Kim BG, Kim SY, et al. In vitro activity and clinical outcomes of clofazimine for nontuberculous mycobacteria pulmonary disease. J Clin Med. 2021 Oct 3;10(19):4581. doi: 10.3390/jcm10194581
   PubMed Web of Science ®Google Scholar
• Pfaeffle HOI, Alameer RM, Marshall MH, et al. Clofazimine for treatment of multidrug-resistant non-tuberculous mycobacteria. Pulm Pharmacol Ther. 2021 Oct;70:102058.
   PubMed Web of Science ®Google Scholar
• McGuffin SA, Pottinger PS, Harnisch JP. Clofazimine in nontuberculous mycobacterial infections: a growing niche. Open Forum Infect Dis. 2017 Summer;4(3):ofx147. doi: 10.1093/ofid/ofx147.
   PubMed Web of Science ®Google Scholar
• Shuto H, Komiya K, Goto A, et al. Efficacy and safety of fluoroquinolone-containing regimens in treating pulmonary Mycobacterium avium complex disease: a propensity score analysis. PLoS One. 2020;15(7):e0235797. doi: 10.1371/journal.pone.0235797
   PubMed Web of Science ®Google Scholar
• Flume PA, Griffith DE, Chalmers JD, et al. Development of drugs for nontuberculous mycobacterial disease: clinicians’ interpretation of a US food and drug administration workshop. Chest. 2021 Feb;159(2):537–543. doi: 10.1016/j.chest.2020.08.2055
   PubMed Web of Science ®Google Scholar
• Wu ML, Aziz DB, Dartois V, et al. NTM drug discovery: status, gaps and the way forward. Drug Discov Today. 2018 Aug;23(8):1502–1519. doi: 10.1016/j.drudis.2018.04.001
   PubMed Web of Science ®Google Scholar
• Ruth MM, van Ingen J. New insights in the treatment of nontuberculous mycobacterial pulmonary disease. Future Microbiol. 2017 Oct;12(13):1109–1112. doi: 10.2217/fmb-2017-0144
   PubMed Web of Science ®Google Scholar
• Locher CP, Jones SM, Hanzelka BL, et al. A novel inhibitor of gyrase B is a potent drug candidate for treatment of tuberculosis and nontuberculosis mycobacterial infections. Antimicrob Agents Chemother. 2015 Mar;59(3):1455–1465. doi: 10.1128/AAC.04347-14
   PubMed Web of Science ®Google Scholar
• Grossman TH, Bartels DJ, Mullin S, et al. Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds. Antimicrob Agents Chemother. 2007 Feb;51(2):657–666. doi: 10.1128/AAC.00596-06
   PubMed Web of Science ®Google Scholar
• Durcik M, Tomasic T, Zidar N, et al. ATP-competitive DNA gyrase and topoisomerase IV inhibitors as antibacterial agents. Expert Opin Ther Pat. 2019 Mar;29(3):171–180. doi: 10.1080/13543776.2019.1575362
   PubMed Web of Science ®Google Scholar
• Henderson SR, Stevenson CEM, Malone B, et al. Structural and mechanistic analysis of ATPase inhibitors targeting mycobacterial DNA gyrase. J Antimicrob Chemother. 2020 Oct 1;75(10):2835–2842. doi: 10.1093/jac/dkaa286
   PubMed Web of Science ®Google Scholar
• Chaudhari K, Surana S, Jain P, et al. Mycobacterium tuberculosis (MTB) GyrB inhibitors: an attractive approach for developing novel drugs against TB. Eur J Med Chem. 2016 Nov 29;124:160–185. doi: 10.1016/j.ejmech.2016.08.034
   PubMed Web of Science ®Google Scholar
• Charifson PS, Grillot AL, Grossman TH, et al. Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships. J Med Chem. 2008 Sep 11;51(17):5243–5263. doi: 10.1021/jm800318d
   PubMed Web of Science ®Google Scholar
• Finn J. Evaluation of WO2012177707 and WO2012097269: vertex’s phosphate prodrugs of gyrase and topoisomerase antibacterial agents. Expert Opin Ther Pat. 2013 Sep;23(9):1233–1237. doi: 10.1517/13543776.2013.820707
   PubMed Web of Science ®Google Scholar
• Brown-Elliott BA, Rubio A, Wallace RJ Jr. In vitro susceptibility testing of a novel benzimidazole, SPR719, against nontuberculous mycobacteria. Antimicrob Agents Chemother. 2018 Nov;62(11). doi: 10.1128/AAC.01503-18.
   PubMed Web of Science ®Google Scholar
• Stokes SS, Vemula R, Pucci MJ. Advancement of GyrB inhibitors for treatment of infections caused by Mycobacterium tuberculosis and non-tuberculous mycobacteria. ACS Infect Dis. 2020 Jun 12;6(6):1323–1331. doi: 10.1021/acsinfecdis.0c00025
   PubMed Web of Science ®Google Scholar
• Nagaraja V, Godbole AA, Henderson SR, et al. DNA topoisomerase I and DNA gyrase as targets for TB therapy. Drug Discov Today. 2017 Mar;22(3):510–518. doi: 10.1016/j.drudis.2016.11.006
   PubMed Web of Science ®Google Scholar
• Hooper DC, Jacoby GA. Topoisomerase inhibitors: fluoroquinolone mechanisms of action and resistance. Cold Spring Harb Perspect Med. 2016 Sep 1;6(9):a025320. doi: 10.1101/cshperspect.a025320
   PubMed Web of Science ®Google Scholar
• Cotroneo N, Stokes SS, Pucci MJ, et al. In vitro activity and in vivo efficacy against non-tuberculous mycobacteria of SPR719, the active moiety of the novel oral benzimidazole prodrug SPR720. J Antimicrob Chemother. 2023. [manuscript submitted].
   Google Scholar
• Rubio A, Stapleton M, Verma D, et al. Potent activity of a novel gyrase inhibitor (SPR719/SPR720) in vitro and in a prolonged acute Mycobacterium abscessus mouse model of infection [poster SUN-539]. (WA) DC: ASM Microbe/American Society for Microbiology; 2018.
   Google Scholar
• Pennings LJ, Ruth MM, Wertheim HFL, et al. The benzimidazole SPR719 shows promising concentration-dependent activity and synergy against nontuberculous mycobacteria. Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.02469-20
   Web of Science ®Google Scholar
• Pidot SJ, Porter JL, Lister T, et al. In vitro activity of SPR719 against Mycobacterium ulcerans, Mycobacterium marinum and Mycobacterium chimaera. PLoS Negl Trop Dis. 2021 Jul;15(7):e0009636. doi: 10.1371/journal.pntd.0009636
   PubMed Web of Science ®Google Scholar
• Aragaw WW, Cotroneo N, Stokes S, et al. In vitro resistance against DNA gyrase inhibitor SPR719 in Mycobacterium avium and Mycobacterium abscessus. Microbiol Spectr. 2022 Feb 23;10(1):e0132121. doi: 10.1128/spectrum.01321-21
   PubMed Web of Science ®Google Scholar
• Deshpande D, Kuret D, Cirrincione K, et al. Pharmacokinetics/Pharmacodynamics of the novel gyrase inhibitor SPR719/SPR720 and clinical dose selection to treat pulmonary Mycobacterium avium-complex disease. Open Forum Infect Dis. 1659 2020 Dec 31;7(Suppl 1):S817. doi: 10.1093/ofid/ofaa439.1837
   Google Scholar
• Verma D, Peterson C, Stokes S, et al. SPR720, a novel aminobenzimidazole gyrase inhibitor, demonstrates potent efficacy against Mycobacterium avium ATCC 700898 in a chronic C3HeBFeJ mouse infection model [poster 1637]. Arlington VA: IDWeek/IDSA; 2020.
   Google Scholar
• Talley AK, Thurston A, Moore G, et al. First-in-human evaluation of the safety, tolerability, and pharmacokinetics of SPR720, a novel oral bacterial DNA gyrase (GyrB) inhibitor for mycobacterial infections. Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0120821. doi: 10.1128/AAC.01208-21
   PubMed Web of Science ®Google Scholar